Your browser is no longer supported. Please, upgrade your browser.
Settings
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-1.86 Insider Own1.50% Shs Outstand148.51M Perf Week2.31%
Market Cap2.43B Forward P/E- EPS next Y-0.40 Insider Trans110.95% Shs Float142.78M Perf Month-9.61%
Income-233.80M PEG- EPS next Q-0.14 Inst Own78.30% Short Float19.73% Perf Quarter41.36%
Sales3.30M P/S736.70 EPS this Y-135.30% Inst Trans7.55% Short Ratio9.26 Perf Half Y72.86%
Book/sh0.11 P/B148.82 EPS next Y81.00% ROA-178.30% Target Price20.33 Perf Year230.04%
Cash/sh0.94 P/C17.39 EPS next 5Y- ROE391.00% 52W Range4.73 - 18.93 Perf YTD1.30%
Dividend- P/FCF- EPS past 5Y-44.67% ROI-200.90% 52W High-13.52% Beta1.51
Dividend %- Quick Ratio1.30 Sales past 5Y-37.60% Gross Margin77.00% 52W Low246.09% ATR0.94
Employees138 Current Ratio1.30 Sales Q/Q50.00% Oper. Margin- RSI (14)54.34 Volatility4.85% 5.98%
OptionableYes Debt/Eq1.15 EPS Q/Q93.00% Profit Margin- Rel Volume0.37 Prev Close16.38
ShortableYes LT Debt/Eq1.15 EarningsFeb 08 AMC Payout- Avg Volume3.04M Price16.37
Recom1.30 SMA20-0.43% SMA505.18% SMA20045.64% Volume1,134,305 Change-0.06%
May-05-17Upgrade Wells Fargo Market Perform → Outperform
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Jul-29-15Downgrade Jefferies Buy → Hold
Aug-27-14Downgrade R. F. Lafferty Buy → Neutral $4
Jan-08-14Initiated Chardan Capital Markets Buy $9
Oct-02-13Reiterated Oppenheimer Outperform $6 → $8
Sep-10-13Initiated R. F. Lafferty Buy $8
Jun-03-13Initiated WallachBeth Buy $6
Aug-31-11Initiated Summer Street Research Buy $8
Jul-28-11Initiated Summer Street Research Buy $8
Jul-13-11Resumed Brean Murray Buy $8
May-17-11Initiated Oppenheimer Outperform $6
Feb-23-11Initiated Wedbush Outperform $6
Jul-03-07Initiated Brean Murray Buy $8
Feb-20-07Initiated Lazard Capital Buy $6
Feb-15-18 08:00AM  Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
07:30AM  Fennec Pharma (FENC): The Most Likely Acquisition Target in Healthcare with 200-300% Upside? ACCESSWIRE
Feb-14-18 07:30AM  Blog Exposure - FDA Accepts Amicus Therapeutics NDA for Migalastat for Treatment of Fabry Disease ACCESSWIRE
Feb-13-18 03:49PM  8 Companies That Could Disappear by 2019 InvestorPlace
Feb-09-18 05:01AM  Immunomedics reports 2Q loss Associated Press
Feb-08-18 04:15PM  Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
Feb-06-18 08:00AM  Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018 GlobeNewswire
Jan-31-18 08:20AM  New Research: Key Drivers of Growth for Cavco Industries, National Commerce, The Providence Service, Cisco, Immunomedics, and Emergent Biosolutions Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-17-18 07:00AM  Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock InvestorPlace
Jan-11-18 08:00AM  Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer GlobeNewswire
Jan-10-18 08:00AM  Todays Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics ACCESSWIRE
Jan-08-18 08:30AM  Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million GlobeNewswire
Jan-04-18 08:45AM  Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 11:34AM  Harry Boxer: These two marijuana stocks are climbing higher MarketWatch
Dec-22-17 11:41AM  ETFs with exposure to Immunomedics, Inc. : December 22, 2017 Capital Cube +6.08%
Dec-21-17 12:23PM  BlackBerry Among Four Stocks Breaking Out Forbes
Dec-13-17 07:02AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-11-17 01:59PM  ETFs with exposure to Immunomedics, Inc. : December 11, 2017 Capital Cube
Dec-08-17 01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace
07:45AM  Immunomedics' Data Is Good News for Seattle Genetics, Too Motley Fool
07:16AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017 Capital Cube
Dec-07-17 08:10AM  Todays Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals ACCESSWIRE +16.16%
Dec-06-17 03:58PM  Why Immunomedics, Inc. Is Soaring Today Motley Fool +13.00%
12:10PM  Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) GlobeNewswire
Nov-30-17 02:00PM  ETFs with exposure to Immunomedics, Inc. : November 30, 2017 Capital Cube
Nov-29-17 08:04AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017 Capital Cube
Nov-28-17 08:05AM  Immunomedics, Full Study Data to be Presented December 6, 2017, BLA Application as Early as 1Q18 ACCESSWIRE
Nov-27-17 08:05AM  Analysis: Positioning to Benefit within Aradigm, General Motors, AT&T, Denbury Resources, Novavax, and Immunomedics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-20-17 07:40AM  Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine ACCESSWIRE
Nov-16-17 08:43AM  Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock Zacks +8.11%
Nov-15-17 08:38AM  Immunomedics (IMMU) Jumps: Stock Rises 5.4% Zacks +5.31%
Nov-14-17 04:07PM  Edited Transcript of IMMU earnings conference call or presentation 9-Nov-17 10:00pm GMT Thomson Reuters StreetEvents +5.40%
12:44PM  Cowen Bets on Immunomedics Securing Accelerated Approval Even After Decreased Overall Survival Seen in IMMU-132 Abstract SmarterAnalyst
Nov-13-17 04:30PM  Why Sears Holdings, Immunomedics, and J.C. Penney Slumped Today Motley Fool -19.35%
09:30AM  Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium GlobeNewswire
07:24AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : November 13, 2017 Capital Cube
Nov-10-17 03:02PM  Why Immunomedics, Inc. Jumped Higher Today Motley Fool +18.77%
08:20AM  Todays Research Reports on Trending Tickers: Endo International and Immunomedics ACCESSWIRE
Nov-09-17 05:21PM  Immunomedics reports 1Q loss Associated Press
04:10PM  Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
04:05PM  Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth GlobeNewswire
01:00PM  Immunomedics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 08:00AM  Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017 GlobeNewswire +6.82%
Oct-31-17 12:13PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : October 31, 2017 Capital Cube -5.13%
11:42AM  ETFs with exposure to Immunomedics, Inc. : October 31, 2017 Capital Cube
Oct-30-17 08:11AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : October 30, 2017 Capital Cube
Oct-27-17 09:35AM  Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers TheStreet.com +6.18%
Oct-23-17 08:37AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks
Oct-05-17 12:21PM  Edited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT Thomson Reuters StreetEvents -8.50%
Oct-03-17 11:19AM  ETFs with exposure to Immunomedics, Inc. : October 3, 2017 Capital Cube
Sep-15-17 04:30PM  Why Carnival, Immunomedics, and Fitbit Slumped Today Motley Fool
08:00AM  Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock GlobeNewswire
Sep-11-17 09:00AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks +5.17%
07:00AM  Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer GlobeNewswire
Aug-30-17 08:00AM  Immunomedics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-28-17 05:33PM  ETFs with exposure to Immunomedics, Inc. : August 28, 2017 Capital Cube +14.07%
03:30PM  Here's Why Immunomedics Rose as Much as 14.2% Today Motley Fool
Aug-24-17 12:51PM  Harry Boxer: These three biotech stocks are breaking out MarketWatch +9.88%
10:45AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q4, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-23-17 08:48AM  Immunomedics (IMMU) Catches Eye: Stock Up 5.1% Zacks
08:41AM  Zacks.com featured highlights: Glu Mobile, Calumet Specialty Products Partners, The Bancorp, Immunomedics and Hudbay Minerals Zacks
Aug-22-17 10:44AM  Immunomedics' Progress in Phase II Cancer Study Encouraging Zacks +5.11%
08:23AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : August 22, 2017 Capital Cube
Aug-21-17 02:02PM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: 2017 By the Numbers : August 21, 2017 Capital Cube +7.01%
08:00AM  Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer GlobeNewswire
Aug-17-17 08:50AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks
Aug-16-17 09:21PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : August 17, 2017 Capital Cube
09:14PM  Immunomedics reports 4Q loss Associated Press
04:00PM  Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline GlobeNewswire
Aug-07-17 04:00PM  Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2017 Results GlobeNewswire
Aug-03-17 09:46AM  Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : August 3, 2017 Capital Cube
Jul-10-17 02:40PM  ETFs with exposure to Immunomedics, Inc. : July 10, 2017 Capital Cube
09:00AM  Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers GlobeNewswire
Jun-29-17 03:11PM  Immunomedics Announces Results of Special Stockholder Meeting GlobeNewswire
08:35AM  Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock Zacks
Jun-27-17 03:20PM  ETFs with exposure to Immunomedics, Inc. : June 27, 2017 Capital Cube
Jun-16-17 03:54PM  ETFs with exposure to Immunomedics, Inc. : June 16, 2017 Capital Cube
Jun-07-17 11:05AM  Three Junior Biotechs Ready to Run Investopedia
Jun-05-17 02:22PM  ETFs with exposure to Immunomedics, Inc. : June 5, 2017 Capital Cube
Jun-01-17 08:00AM  Immunomedics to Present at Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-26-17 09:33AM  Biotech Movers: Immunomedics, Aerie, Exelixis TheStreet.com
May-25-17 12:41PM  ETFs with exposure to Immunomedics, Inc. : May 25, 2017 Capital Cube
May-24-17 09:51AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017 Capital Cube
May-18-17 05:00AM  Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-11-17 09:21PM  Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents +6.14%
May-10-17 04:10PM  Immunomedics reports 3Q loss Associated Press
04:00PM  Immunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program Developments GlobeNewswire
08:15AM  Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results GlobeNewswire
May-08-17 05:53PM  The Head-Scratching Reason Immunomedics Rose by as Much as 12% Motley Fool +8.02%
08:25AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : May 8, 2017 Capital Cube
08:00AM  Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics Accesswire
06:00AM  Immunomedics Breaks Out, But Will It Last? Investopedia
May-06-17 09:10AM  Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated? 24/7 Wall St.
May-05-17 04:32PM  Immunomedics, Seattle Genetics Scrap License Deal TheStreet.com +17.56%
04:22PM  Why Immunomedics, MercadoLibre, and Pearson Jumped Today Motley Fool
01:57PM  Why Immunomedics, Inc. Rocketed Today Motley Fool
10:42AM  Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated TheStreet.com
08:46AM  Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value Business Wire
Apr-25-17 04:18PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : April 25, 2017 Capital Cube +6.98%
Apr-24-17 08:41AM  Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : April 24, 2017 Capital Cube
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARKISON BRIAN ADirectorNov 20Option Exercise3.1615,00047,40099,178Nov 21 05:00 PM
MARKISON BRIAN ADirectorNov 20Sale11.898,39099,72490,788Nov 21 05:00 PM
venBio Select Advisor LLCDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 15 05:48 PM
venBio Select Advisor LLCDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 15 05:48 PM
GOLDENBERG CYNTHIA LDirectorSep 01Sale12.9010,000129,000778,219Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksSep 01Sale12.9010,000129,0003,395,578Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorAug 31Sale12.3810,000123,750788,219Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksAug 31Sale12.3810,000123,7503,405,578Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorAug 28Sale11.5215,000172,841798,219Aug 28 08:54 PM
GOLDENBERG DAVID MSee RemarksAug 28Sale11.5610,000115,5913,415,578Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 24Sale10.2425,000256,105813,219Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 23Sale9.5010,00095,000838,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 23Sale9.5010,00095,0003,455,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 22Sale9.5010,00095,000848,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 22Sale9.5010,00095,0003,465,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 21Sale8.9720,000179,426858,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 21Sale8.9720,000179,4263,475,578Aug 23 09:00 PM
ASFI Asta Funding, Inc. daily Stock Chart
ASFI [NASD]
Asta Funding, Inc.
Index- P/E- EPS (ttm)-0.09 Insider Own70.98% Shs Outstand7.21M Perf Week-4.43%
Market Cap76.79M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.92M Perf Month50.00%
Income-0.70M PEG- EPS next Q- Inst Own17.00% Short Float0.70% Perf Quarter48.95%
Sales48.00M P/S1.60 EPS this Y315.00% Inst Trans-0.73% Short Ratio0.48 Perf Half Y43.92%
Book/sh18.57 P/B0.57 EPS next Y- ROA-0.30% Target Price8.00 Perf Year3.65%
Cash/sh2.30 P/C4.63 EPS next 5Y10.00% ROE-0.50% 52W Range6.15 - 11.50 Perf YTD42.00%
Dividend- P/FCF- EPS past 5Y-2.40% ROI4.30% 52W High-7.39% Beta-0.16
Dividend %- Quick Ratio- Sales past 5Y6.30% Gross Margin91.90% 52W Low73.17% ATR0.62
Employees188 Current Ratio- Sales Q/Q-21.60% Oper. Margin-4.30% RSI (14)66.39 Volatility11.02% 5.06%
OptionableYes Debt/Eq0.70 EPS Q/Q3.60% Profit Margin-1.50% Rel Volume0.19 Prev Close10.60
ShortableYes LT Debt/Eq0.63 EarningsFeb 15 BMO Payout- Avg Volume28.18K Price10.65
Recom- SMA2016.61% SMA5031.12% SMA20039.35% Volume5,306 Change0.47%
Feb-24-09Upgrade Keefe Bruyette Mkt Perform → Outperform $16
Jun-02-08Reiterated Kaufman Bros Hold $5 → $9
May-30-08Initiated Keefe Bruyette Mkt Perform $8
May-05-08Reiterated Kaufman Bros Hold $25 → $15
Feb-12-08Reiterated Kaufman Bros Hold $30 → $25
Jan-09-08Reiterated Kaufman Bros Hold $40 → $30
Dec-18-07Downgrade Kaufman Bros Buy → Hold $55 → $40
Jun-29-07Initiated Kaufman Bros Buy $55
Feb-22-18 03:00PM  Asta Funding, Inc. Announces Receipt of Nasdaq Non-Compliance Letter GlobeNewswire
Feb-05-18 04:45PM  Asta Funding, Inc. Announces $5.30 Per Share Special Cash Dividend GlobeNewswire
Jan-19-18 12:15PM  Asta Funding, Inc. Announces Receipt of Nasdaq Non-Compliance Letter GlobeNewswire
Jan-18-18 05:12PM  Asta Funding, Inc. Announces Decision to Restate 2014, 2015 and 2016 Financial Statements GlobeNewswire
Dec-20-17 06:05PM  How Does Asta Funding Inc (NASDAQ:ASFI)s Prospect Stack Up Next To Its Financial Peers? Simply Wall St.
11:33AM  ETFs with exposure to Asta Funding, Inc. : December 20, 2017 Capital Cube
Dec-19-17 02:55PM  Is Asta Funding Incs (NASDAQ:ASFI) CEO Salary Justified? Simply Wall St.
Dec-12-17 06:04AM  Who Are The Largest Shareholders In Asta Funding Inc (undefined:ASFI)? Simply Wall St.
Dec-06-17 04:41PM  Want To Invest In Asta Funding Inc (ASFI)? Heres How It Performed Lately Simply Wall St.
Dec-05-17 12:20PM  ETFs with exposure to Asta Funding, Inc. : December 5, 2017 Capital Cube
Oct-18-17 09:36AM  ETFs with exposure to Asta Funding, Inc. : October 18, 2017 Capital Cube
Oct-09-17 03:19PM  Why Asta Funding Inc (ASFI) May Not Be As Efficient As Its Industry Simply Wall St.
Sep-28-17 10:09AM  ETFs with exposure to Asta Funding, Inc. : September 28, 2017 Capital Cube
Sep-21-17 12:01PM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q3, 2017 By the Numbers : September 21, 2017 Capital Cube
Aug-15-17 04:11PM  Edited Transcript of ASFI earnings conference call or presentation 9-Aug-17 1:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 11:39PM  Asta Funding posts 3Q profit Associated Press
08:30AM  Asta Funding Announces Results for The Third Quarter Ended June 30, 2017 GlobeNewswire
Jul-13-17 03:29PM  ETFs with exposure to Asta Funding, Inc. : July 13, 2017 Capital Cube
Jun-19-17 02:56PM  ETFs with exposure to Asta Funding, Inc. : June 19, 2017 Capital Cube
Jun-16-17 11:35AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q2, 2017 By the Numbers : June 16, 2017 Capital Cube +8.18%
08:15AM  Featured Company News - WEX Announces an Agreement with GasBuddy; Set to Expand the Retail Gasoline Accesswire
Jun-09-17 02:15PM  Edited Transcript of ASFI earnings conference call or presentation 26-May-17 1:30pm GMT Thomson Reuters StreetEvents
May-30-17 04:00PM  Asta Funding, Inc. Announces Receipt of Nasdaq Compliance Letter GlobeNewswire
May-26-17 08:12AM  Asta Funding reports 2Q loss Associated Press
08:00AM  Asta Funding Announces Results for the Second Quarter Ended March 31, 2017 GlobeNewswire
May-23-17 04:05PM  Asta Funding, Inc. Announces Receipt of Nasdaq Non-Compliance Letter GlobeNewswire
May-15-17 08:00PM  Asta Funding, Inc. Announces Decision to Restate First Quarter 2017 GlobeNewswire
Apr-10-17 04:56PM  CBC Settlement Funding Completes BBRVII 2017--Private Placement Note Offering GlobeNewswire -5.26%
Mar-16-17 05:23PM  ASTA FUNDING INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant
Mar-14-17 12:06PM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q1, 2017 By the Numbers : March 14, 2017 Capital Cube
12:06PM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q1, 2017 By the Numbers : March 14, 2017
Feb-22-17 04:05PM  Asta Funding, Inc. Announces Final Results of its Tender Offer GlobeNewswire
Feb-16-17 04:05PM  Asta Funding, Inc. Announces Preliminary Results of its Tender Offer GlobeNewswire
Feb-15-17 01:04PM  ASTA FUNDING INC Financials
Feb-09-17 09:00PM  Edited Transcript of ASFI earnings conference call or presentation 9-Feb-17 2:00pm GMT Thomson Reuters StreetEvents
09:05AM  ASTA FUNDING INC Files SEC form 8-K, Results of Operations and Financial Condition
08:38AM  Asta Funding reports 1Q loss Associated Press
08:00AM  Asta Funding Announces Results for The First Quarter Ended December 31, 2016 GlobeNewswire
Feb-02-17 08:41AM  ASTA FUNDING INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Asta Funding, Inc. Extends Tender Offer Until 11:59 p.m., February 15, 2017 GlobeNewswire
Jan-19-17 08:42AM  ASTA FUNDING INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:15AM  Asta Funding, Inc. Announces Commencement of Tender Offer to Purchase Up to 5,314,009 Shares of its Common Stock GlobeNewswire
Jan-09-17 09:27AM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or By
09:15AM  Asta Funding Reaches Agreement with Mangrove Partners GlobeNewswire
Dec-22-16 12:51PM  ETFs with exposure to Asta Funding, Inc. : December 22, 2016 Capital Cube
12:51PM  ETFs with exposure to Asta Funding, Inc. : December 22, 2016
Dec-16-16 08:11AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: 2016 By the Numbers : December 16, 2016 Capital Cube
08:11AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: 2016 By the Numbers : December 16, 2016
Dec-14-16 12:19PM  Edited Transcript of ASFI earnings conference call or presentation 14-Dec-16 3:00pm GMT Thomson Reuters StreetEvents
10:01AM  ASTA FUNDING INC Files SEC form 8-K, Results of Operations and Financial Condition
09:00AM  Asta Funding Announces Results for The Fourth Quarter and Fiscal Year Ended September 30, 2016 GlobeNewswire
Nov-28-16 04:07PM  ASTA FUNDING INC Files SEC form 8-K, Termination of a Material Definitive Agreement
Nov-15-16 04:17PM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off
04:05PM  Asta Funding Announces the Formation of a Wholly Owned Subsidiary to Expand its Personal Injury Claims Funding Business GlobeNewswire
Nov-01-16 11:49AM  ETFs with exposure to Asta Funding, Inc. : November 1, 2016 Capital Cube
11:49AM  ETFs with exposure to Asta Funding, Inc. : November 1, 2016
Oct-05-16 10:05AM  ETFs with exposure to Asta Funding, Inc. : October 5, 2016 -5.44%
Sep-06-16 09:54AM  ETFs with exposure to Asta Funding, Inc. : September 6, 2016
Aug-18-16 11:32AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q3, 2016 By the Numbers : August 18, 2016
Aug-17-16 12:03PM  ASTA FUNDING INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
08:00AM  Asta Funding Appoints Mark Levenfus as New member to its Board GlobeNewswire
Aug-09-16 02:34PM  Edited Transcript of ASFI earnings conference call or presentation 9-Aug-16 2:00pm GMT
12:18PM  ASTA FUNDING INC Files SEC form 8-K, Results of Operations and Financial Condition
09:26AM  Asta Funding posts 3Q profit
07:45AM  Asta Funding Announces Results for Three and Nine Months Ended June 30, 2016 GlobeNewswire
07:07AM  Q3 2016 Asta Funding Inc Earnings Release - Before Market Open
Aug-04-16 08:00AM  Asta Funding, Inc. to Report Financial Results for the Three and Nine Months Ended June 30, 2016 GlobeNewswire
Jul-11-16 05:31PM  ASTA FUNDING INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
05:12PM  CBC Settlement Funding Completes BBRVI 2016-A Private Placement Note Offering GlobeNewswire
May-26-16 07:11PM  ETFs with exposure to Asta Funding, Inc. : May 26, 2016
05:12PM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
May-19-16 05:23PM  ASTA FUNDING INC Files SEC form 8-K, Other Events
May-18-16 11:20AM  Asta Funding, Inc. :ASFI-US: Earnings Analysis: Q2, 2016 By the Numbers
May-17-16 11:31AM  Asta Funding Inc (ASFI): Mangrove Partners Ups Its Stake and Demands Representation on the Board at Insider Monkey
May-13-16 02:01PM  Edited Transcript of ASFI earnings conference call or presentation 13-May-16 1:00pm GMT
09:00AM  Asta Funding, Inc. Announces Final Results of Its Modified Dutch Auction Tender Offer GlobeNewswire
May-10-16 06:05PM  ASTA FUNDING INC Files SEC form 10-Q, Quarterly Report
04:19PM  Asta Funding reports 2Q loss
04:00PM  Asta Funding, Inc. Announces Financial Results for the Second Quarter and First Six Months of Fiscal 2016 GlobeNewswire
May-03-16 04:45PM  Asta Funding, Inc. Announces Clarifying Amendment of Its Tender Offer to Purchase Up to 3,000,000 Shares of Its Common Stock GlobeNewswire
Apr-21-16 02:31PM  Asta Funding Reiterates Its Rejection Of Unsolicited Tender Offer Benzinga
12:50PM  Asta Funding, Inc.s Board of Directors Reaffirms Recommendation that Shareholders Reject Amended Unsolicited Tender Offer GlobeNewswire
Apr-15-16 02:55PM  Mangrove Announces Increase of Purchase Price and Extension of Expiration Date of Tender Offer of Asta Funding, Inc. PR Newswire
Apr-11-16 03:19PM  Asta Funding, Inc. Announces Commencement of Tender Offer to Purchase Up to 3,000,000 Shares of Its Common Stock GlobeNewswire
Apr-06-16 01:19PM  Mangrove Partners Continues Activist Battle Against Asta Funding
Apr-05-16 05:56PM  Mangrove Announces Waiver of Condition of Tender Offer of Asta Funding, Inc. PR Newswire
Apr-04-16 04:12PM  Asta Funding, Inc.: Strong price momentum but will it sustain?
Mar-31-16 10:00PM  Asta Funding, Inc.s Board of Directors Rejects Unsolicited Tender Offer GlobeNewswire
04:16PM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-17-16 01:01PM  ASTA FUNDING INC Files SEC form 8-K, Other Events
12:38PM  Asta Funding, Inc. Extends the Rule 10b5-1 Plan in Conjunction With Share Repurchase Program GlobeNewswire
Mar-15-16 05:40PM  ASTA FUNDING INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off +7.58%
09:25AM  Mangrove Announces Intention to Commence Tender Offer for up to 3,000,000 Shares of Common Stock of Asta Funding, Inc. PR Newswire
Mar-03-16 02:30PM  ASTA FUNDING INC Files SEC form 8-K, Other Events +7.75%
Mar-02-16 04:26PM  Asta Funding Inc (ASFI): Hedge Fund Mangrove Partners Snapping Up at Insider Monkey
Feb-16-16 02:13PM  Asta Funding, Inc. Earnings Analysis: Q1, 2016 By the Numbers
Feb-09-16 11:15PM  Edited Transcript of ASFI earnings conference call or presentation 9-Feb-16 9:00pm GMT
12:31PM  ASTA FUNDING INC Files SEC form 8-K, Results of Operations and Financial Condition
08:21AM  Asta Funding posts 1Q profit
08:00AM  Asta Funding, Inc. Announces Earnings for First Quarter Fiscal 2016 GlobeNewswire
Asta Funding, Inc., together with its subsidiaries, engages in the consumer receivable business in the United States. The company operates through four segments: Consumer Receivables, Personal Injury Claims, Structured Settlements, and GAR Disability Advocacy. The Consumer Receivables segment involved in the purchase, management, and servicing distressed consumer receivables, including charged-off receivables consisting of accounts that have been written-off by the originators and might have been previously serviced by collection agencies; semi-performing receivables, including accounts where the debtor is currently making partial or irregular monthly payments, but the accounts might have been written-off by the originators; and performing receivables comprising accounts where the debtor is making regular monthly payments that might or might not have been delinquent in the past. Its distressed consumer receivables include MasterCard, Visa, and other credit card accounts, which were charged-off by the issuers or providers for non-payment. The Personal Injury Claims segment invests in funding personal injury claims. The Structured Settlements segment purchases periodic structured settlements and annuity policies from individuals in exchange for a lump sum payment. The GAR Disability Advocacy segment obtains and represents individuals in their claims for social security disability and supplemental security income benefits from the social security administration. Asta Funding, Inc. was founded in 1994 and is headquartered in Englewood Cliffs, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Berman SethSecretary & General CounselFeb 13Option Exercise2.952,5007,3752,500Feb 15 12:24 PM
Levenfus MarkDirectorJun 13Buy7.133,00021,3903,000Jun 15 10:46 AM
SKY Skyline Corporation daily Stock Chart
SKY [NYSE]
Skyline Corporation
Index- P/E41.43 EPS (ttm)0.50 Insider Own17.75% Shs Outstand8.46M Perf Week-2.98%
Market Cap176.31M Forward P/E- EPS next Y- Insider Trans9.67% Shs Float6.90M Perf Month-2.93%
Income4.40M PEG- EPS next Q- Inst Own52.50% Short Float4.82% Perf Quarter72.37%
Sales227.30M P/S0.78 EPS this Y-99.70% Inst Trans1.05% Short Ratio3.90 Perf Half Y106.34%
Book/sh3.58 P/B5.82 EPS next Y- ROA7.80% Target Price- Perf Year75.86%
Cash/sh1.45 P/C14.33 EPS next 5Y- ROE16.80% 52W Range5.07 - 24.99 Perf YTD62.18%
Dividend- P/FCF160.28 EPS past 5Y14.90% ROI1.20% 52W High-16.61% Beta2.26
Dividend %- Quick Ratio1.50 Sales past 5Y5.30% Gross Margin11.60% 52W Low311.05% ATR1.35
Employees1200 Current Ratio2.20 Sales Q/Q-10.00% Oper. Margin2.10% RSI (14)53.69 Volatility5.84% 7.36%
OptionableNo Debt/Eq0.09 EPS Q/Q588.10% Profit Margin1.90% Rel Volume0.41 Prev Close20.96
ShortableYes LT Debt/Eq0.09 EarningsJan 18 AMC Payout0.00% Avg Volume85.38K Price20.84
Recom- SMA20-4.15% SMA5013.65% SMA20080.52% Volume35,060 Change-0.57%
Jan-23-18 07:00PM  Skyline and Champion Home Builders to Host Conference Call on Proposed Business Combination on Thursday, January 25 PR Newswire
Jan-11-18 05:59PM  Skyline posts 2Q profit Associated Press
05:30PM  Skyline Reports Second Quarter And First Half Results PR Newswire
Jan-09-18 07:20AM  Wired News Skyline and Champion Home Builders Announce Agreement to Merge Operations ACCESSWIRE
Jan-05-18 04:47PM  2 Stocks Jump on Friday GuruFocus.com +48.09%
12:00PM  [$$] PE-Backed Champion Enterprises and Skyline to Combine Operations The Wall Street Journal
09:00AM  Skyline and Champion Home Builders Announce Agreement on Business Combination to Create the Nation's Largest Publicly Traded Factory-Built Housing Company PR Newswire
Dec-27-17 11:49AM  ETFs with exposure to Skyline Corp. : December 27, 2017 Capital Cube
Dec-11-17 02:09PM  ETFs with exposure to Skyline Corp. : December 11, 2017 Capital Cube
Nov-29-17 12:20PM  ETFs with exposure to Skyline Corp. : November 29, 2017 Capital Cube
Nov-17-17 06:01AM  [$$] Drones will reshape how we build our cities Financial Times
Nov-14-17 02:50PM  ETFs with exposure to Skyline Corp. : November 14, 2017 Capital Cube
Nov-03-17 12:33PM  ETFs with exposure to Skyline Corp. : November 3, 2017 Capital Cube
Oct-23-17 11:03AM  ETFs with exposure to Skyline Corp. : October 23, 2017 Capital Cube +7.80%
Oct-10-17 11:49AM  ETFs with exposure to Skyline Corp. : October 10, 2017 Capital Cube -6.85%
Oct-09-17 10:08AM  Skyline Corp. :SKY-US: Earnings Analysis: Q1, 2018 By the Numbers : October 9, 2017 Capital Cube
Oct-06-17 05:40PM  Skyline posts 1Q profit Associated Press +6.09%
05:30PM  Skyline Reports First Quarter Results PR Newswire
Sep-07-17 01:54PM  ETFs with exposure to Skyline Corp. : September 7, 2017 Capital Cube -7.60%
Aug-24-17 04:07PM  ETFs with exposure to Skyline Corp. : August 24, 2017 Capital Cube
Aug-15-17 10:48AM  Skyline Corp. :SKY-US: Earnings Analysis: Q4, 2017 By the Numbers : August 15, 2017 Capital Cube
Aug-11-17 10:52PM  Skyline posts 4Q profit Associated Press
05:30PM  Skyline Reports Fourth Quarter And Year-End Results PR Newswire
Aug-09-17 04:03PM  ETFs with exposure to Skyline Corp. : August 9, 2017 Capital Cube
Jul-26-17 01:33PM  Skyline Corp.: Strong price momentum but will it sustain? Capital Cube +16.30%
Jun-14-17 05:30PM  Skyline Corporation Announces Director Retirements PR Newswire
Jun-02-17 06:00PM  United Way of Elkhart County Honors Skyline Corporation PR Newswire +5.42%
May-05-17 02:34PM  Skyline Corp.: Strong price momentum but will it sustain? Capital Cube +6.06%
May-01-17 04:25PM  ETFs with exposure to Skyline Corp. : May 1, 2017 Capital Cube
Apr-19-17 02:36PM  ETFs with exposure to Skyline Corp. : April 19, 2017 Capital Cube +5.58%
Apr-17-17 09:21AM  Skyline Corp. :SKY-US: Earnings Analysis: Q3, 2017 By the Numbers : April 17, 2017 Capital Cube -27.81%
Apr-14-17 05:30PM  Skyline Reports Third Quarter And First Nine Months Results PR Newswire
Mar-07-17 04:56PM  SKYLINE CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities -7.81%
Mar-02-17 04:58PM  SKYLINE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Mar-01-17 05:30PM  Skyline Corporation Names Jeff Newport Chief Operating Officer PR Newswire
05:09PM  SKYLINE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Feb-21-17 05:03PM  SKYLINE CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
Feb-10-17 05:00PM  Skyline "Brings America Home" at 2017 Louisville Manufactured Housing Show PR Newswire
Jan-25-17 05:00PM  RV Business Top Debuts for 2017 - Shore Park by Skyline, model 1969CTA PR Newswire
Jan-19-17 01:57PM  ETFs with exposure to Skyline Corp. : January 19, 2017 Capital Cube
01:57PM  ETFs with exposure to Skyline Corp. : January 19, 2017
Jan-18-17 01:04PM  SKYLINE CORP Financials
Jan-16-17 09:09AM  Skyline Corp. :SKY-US: Earnings Analysis: Q2, 2017 By the Numbers : January 16, 2017 Capital Cube
09:09AM  Skyline Corp. :SKY-US: Earnings Analysis: Q2, 2017 By the Numbers : January 16, 2017
Jan-13-17 05:11PM  SKYLINE CORP Files SEC form 8-K, Change in Directors or Principal Officers -7.51%
Jan-12-17 05:30PM  Skyline Reports Second Quarter And First Half Results PR Newswire
05:08PM  Skyline reports 2Q loss Associated Press
05:04PM  SKYLINE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Dec-15-16 10:59AM  Murdoch's Fox To Buy European Broadcaster Sky For $14.6B (FOX, SKY) Investopedia
10:59AM  Murdoch's Fox To Buy European Broadcaster Sky For $14.6B (FOX, SKY) at Investopedia
Dec-13-16 01:30PM  ETFs with exposure to Skyline Corp. : December 13, 2016 Capital Cube
01:30PM  ETFs with exposure to Skyline Corp. : December 13, 2016
Dec-09-16 12:04PM  Bank shares pull back, keeping gain on FTSE 100 in check MarketWatch
Dec-02-16 01:15PM  ETFs with exposure to Skyline Corp. : December 2, 2016
Nov-11-16 03:40PM  Skyline Corp.: Strong price momentum but will it sustain?
Oct-28-16 03:19PM  ETFs with exposure to Skyline Corp. : October 28, 2016
Oct-18-16 09:09AM  Skyline Corp. :SKY-US: Earnings Analysis: Q1, 2017 By the Numbers : October 18, 2016
Oct-13-16 05:30PM  Skyline Reports First Quarter Results PR Newswire
05:13PM  Skyline posts 1Q profit
05:04PM  SKYLINE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
05:01PM  SKYLINE CORP Files SEC form 10-Q, Quarterly Report
Oct-12-16 05:00PM  Jeffrey Legault, P.E. is the Recipient of the Prestigious Frank Walter Standards Award from MHI PR Newswire
Oct-07-16 10:15AM  ETFs with exposure to Skyline Corp. : October 7, 2016
Sep-20-16 05:30PM  Skyline Holds Annual Shareholder Meeting PR Newswire
04:55PM  SKYLINE CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events
Aug-05-16 05:41PM  Skyline posts 4Q profit
05:30PM  Skyline Reports Results For Fiscal 2016 Fourth Quarter And Year End PR Newswire
05:00PM  SKYLINE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:59PM  SKYLINE CORP Files SEC form 10-K, Annual Report
Aug-03-16 01:54AM  Sky Plc :SKY-GB: Earnings Analysis: For the six months ended June 30, 2016 : August 3, 2016
Jul-11-16 02:18PM  [$$] US autos: Adding new routes at Financial Times
Jul-05-16 05:30PM  Scott Parkhurst Joins Skyline Corporation As National Sales Manager PR Newswire
04:59PM  SKYLINE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
Jun-27-16 03:40PM  ETFs with exposure to Skyline Corp. : June 27, 2016
07:00AM  The Impact of Brexit on the Stocks We Cover at Morningstar
Jun-24-16 08:50AM  Brexit Fears Unfairly Hit European Communication Stocks at Morningstar
Jun-22-16 11:01AM  Skyline Corp. :SKY-US: Earnings Analysis: Q3, 2016 By the Numbers : June 22, 2016
May-16-16 06:02PM  SKYLINE CORP Files SEC form 8-K, Other Events
05:30PM  Skyline To Open Manufacturing Facility In Elkhart, Indiana PR Newswire
May-05-16 08:40AM  BT to invest 6 bln pounds on broadband and mobile upgrades Reuters
May-04-16 04:38PM  ETFs with exposure to Skyline Corp. : May 4, 2016
Apr-26-16 11:15AM  Easy Come, Easy Go: Skyline Sinks After Rally Fueled By Mistaken Identity at Barrons.com -15.53%
11:12AM  TheStreetSweeper Goes Short Skyline: Says Investor Error Is Main Reason Shares Are Up
Apr-22-16 04:27PM  ETFs with exposure to Skyline Corp. : April 22, 2016 +8.77%
Apr-21-16 05:02AM  European Stocks Edge Higher Before ECB Meeting at TheStreet +17.26%
Apr-14-16 05:30PM  Skyline Reports Results For Fiscal 2016 Third Quarter And First Nine Months PR Newswire
04:58PM  SKYLINE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:57PM  SKYLINE CORP Files SEC form 10-Q, Quarterly Report
Mar-10-16 04:10AM  Vice's new TV channel VICELAND will launch on Sky TV in the UK
Mar-09-16 10:56AM  Vice's new TV channel Viceland will launch on Sky TV in the UK in September
Feb-04-16 05:00PM  Skyline Appoints Jeff Newport As Senior Vice President Of Operations PR Newswire
04:56PM  SKYLINE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Jan-20-16 11:12AM  Skyline Corp. Earnings Analysis: Q2, 2016 By the Numbers
Jan-14-16 05:30PM  Skyline Reports Fiscal 2016 Second Quarter And First Half Results PR Newswire
04:57PM  SKYLINE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:55PM  SKYLINE CORP Files SEC form 10-Q, Quarterly Report
Nov-24-15 06:08AM  How Does Smart Money Feel About Acura Pharmaceuticals, Inc. (ACUR)? at Insider Monkey
Nov-12-15 08:27AM  SKYLINE CORP Files SEC form 8-K, Other Events
Oct-23-15 09:30AM  Time to Go Long These Three Stocks? Insider Buying Metric Suggests So; Valeant Pharmaceuticals Intl Inc. (VRX) Among Them at Insider Monkey
Oct-19-15 10:44AM  Skyline Corp. Earnings Q1, 2016
Skyline Corporation designs, produces, and markets manufactured housing, modular housing, and park models to independent dealers and manufactured housing communities in the United States and Canada. The company's manufactured housing models include two to four bedrooms, kitchen, dining area, living room, one or two bathrooms, kitchen appliances, and central heating and cooling products, as well as exterior dormers and windows, interior or exterior accent columns, fireplaces, and whirlpool tubs. Its park models provide temporary living accommodations for individuals seeking leisure travel and outdoor recreation, and are marketed under the Shore Park trademark. As of May 31, 2017, it sold 3,679 manufactured homes, 313 modular homes, and 447 park models in suburban and rural areas. Skyline Corporation was founded in 1951 and is headquartered in Elkhart, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GENDELL JEFFREY L ET AL10% OwnerJan 08Buy17.488,946156,3761,265,493Jan 09 04:30 PM
GENDELL JEFFREY L ET AL10% OwnerJan 05Buy16.8740,020675,3351,256,547Jan 09 04:30 PM
GENDELL JEFFREY L ET AL10% OwnerNov 03Buy12.454,64857,8681,216,527Nov 06 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerNov 02Buy12.125,00060,6001,211,879Nov 06 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerOct 19Buy11.311,42016,0601,206,879Oct 20 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerOct 18Buy11.2440,000449,6001,205,459Oct 20 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerOct 17Buy11.2617,900201,5541,165,459Oct 18 08:30 PM
GENDELL JEFFREY L ET AL10% OwnerOct 16Buy10.8414,520157,3971,147,559Oct 18 08:30 PM
TONTINE ASSET ASSOCIATES, L.L.10% OwnerJul 21Buy5.8552,000304,2001,133,039Jul 24 08:40 PM
TONTINE ASSET ASSOCIATES, L.L.10% OwnerJul 20Buy5.8043,000249,4001,081,039Jul 24 08:40 PM
SPPI Spectrum Pharmaceuticals, Inc. daily Stock Chart
SPPI [NASD]
Spectrum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.00 Insider Own1.00% Shs Outstand102.90M Perf Week-3.85%
Market Cap2.11B Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float90.40M Perf Month-5.41%
Income-79.60M PEG- EPS next Q-0.25 Inst Own80.70% Short Float10.75% Perf Quarter7.01%
Sales135.00M P/S15.60 EPS this Y-20.20% Inst Trans9.30% Short Ratio8.99 Perf Half Y118.36%
Book/sh3.65 P/B5.61 EPS next Y6.70% ROA-18.40% Target Price29.25 Perf Year255.83%
Cash/sh2.41 P/C8.50 EPS next 5Y- ROE-33.30% 52W Range5.47 - 23.50 Perf YTD7.97%
Dividend- P/FCF- EPS past 5Y-25.30% ROI-17.80% 52W High-12.94% Beta1.59
Dividend %- Quick Ratio4.90 Sales past 5Y-5.40% Gross Margin65.00% 52W Low274.04% ATR1.10
Employees227 Current Ratio5.00 Sales Q/Q9.00% Oper. Margin-53.60% RSI (14)50.61 Volatility4.03% 5.60%
OptionableYes Debt/Eq0.33 EPS Q/Q-1.80% Profit Margin-58.90% Rel Volume0.75 Prev Close20.51
ShortableYes LT Debt/Eq0.33 EarningsMar 07 AMC Payout- Avg Volume1.08M Price20.46
Recom1.50 SMA20-3.33% SMA503.50% SMA20053.24% Volume808,095 Change-0.24%
Dec-18-17Initiated B. Riley FBR, Inc. Buy $26
Oct-24-17Initiated Guggenheim Buy $32
Oct-19-17Reiterated H.C. Wainwright Buy $20 → $29
Oct-04-17Reiterated H.C. Wainwright Buy $14 → $20
Aug-16-17Resumed H.C. Wainwright Buy $14
Feb-10-17Resumed Jefferies Buy
Nov-05-15Reiterated RBC Capital Mkts Outperform $13 → $12
Aug-07-15Reiterated RBC Capital Mkts Outperform $12 → $13
Apr-02-15Initiated FBR Capital Outperform $9
Feb-23-15Downgrade ROTH Capital Buy → Neutral $15 → $7
Jul-15-14Upgrade R. F. Lafferty Sell → Neutral $7.50
Oct-07-13Initiated HC Wainwright Buy $15
May-29-13Initiated Burrill Institutional Research Mkt Outperform $12
Mar-13-13Reiterated RBC Capital Mkts Outperform $19 → $16
Mar-13-13Downgrade WallachBeth Buy → Sell $20 → $5.50
May-02-11Reiterated MLV Capital Buy $12.50 → $20.50
Mar-25-11Initiated RBC Capital Mkts Outperform $12
Dec-07-10Reiterated Morgan Joseph Buy $8 → $10
Jan-12-10Upgrade Morgan Joseph Hold → Buy $8
Oct-14-09Reiterated Rodman & Renshaw Mkt Outperform $10 → $8
Feb-21-18 08:00AM  New Research Coverage Highlights Acacia Research, Zebra Technologies, VSE, Spectrum Pharmaceuticals, Agenus, and Williams Companies Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Feb-15-18 07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the 2018 RBC Capital Markets Global Healthcare Conference on February 22nd Business Wire
Feb-12-18 08:28AM  [$$] Buying United, Selling Lilly, Rambus, Tronc Barrons.com
Feb-07-18 07:00AM  Wired News Spectrum Pharmas ROLONTIS Achieved Primary Endpoint in Phase-3 ADVANCE Study ACCESSWIRE
Feb-06-18 10:10AM  Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study Zacks
08:38AM  Bristol-Myers Squibb, Spectrum Just Reported Key Late Stage Data Market Exclusive
Feb-05-18 09:33AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Spectrum Pharmaceuticals Announces ROLONTIS (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study Business Wire
Feb-02-18 05:06PM  Top 4 Small-Cap Stocks for 2018 Investopedia
Jan-23-18 08:10AM  Todays Research Reports on Trending Tickers: Spectrum Pharmaceuticals and ZIOPHARM Oncology ACCESSWIRE
07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the Noble Capital Markets' Fourteenth Annual Investor Conference Business Wire
Jan-22-18 05:40PM  Spectrum Pharmaceuticals Incs (NASDAQ:SPPI) Earnings Dropped -44.12%, Did Its Industry Show Weakness Too? Simply Wall St. +9.93%
Jan-19-18 10:06AM  Spectrum Pharmaceuticals Up 134% in 6 Months: Here's Why Zacks
Jan-08-18 06:03AM  The 10 Best Stocks of 2017 Motley Fool
Dec-21-17 06:25AM  Spectrum Pharmaceuticals Inc (NASDAQ:SPPI): What Does The Future Look Like? Simply Wall St.
Dec-18-17 09:37AM  Spectrum Pharma Dismisses CEO, Makes Leadership Changes Zacks
Dec-17-17 06:59PM  Spectrum Pharmaceuticals Announces Leadership Changes Business Wire
Dec-13-17 07:00AM  Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH) Business Wire
Dec-12-17 10:32AM  Chart in Focus: Spectrum Pharmaceuticals Financials Market Realist
09:03AM  An Overview of Spectrum Pharmaceuticals Drug Pipeline Market Realist
07:33AM  Spectrum Pharmaceuticals Product Licensing Agreements Market Realist
Dec-11-17 05:10PM  A Look at Spectrum Pharmaceuticals Recent Acquisitions Market Realist
03:36PM  Analysts Recommendations for Spectrum Pharmaceuticals Market Realist
Dec-10-17 08:44PM  18 small-cap stocks that analysts expect to rise at least 50% in 2018 MarketWatch
Dec-04-17 07:00AM  Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017 Business Wire
Nov-27-17 10:06AM  Spectrum Doubles in 3 Months: What's Driving the Rally? Zacks
Nov-20-17 02:41PM  Edited Transcript of SPPI earnings conference call or presentation 2-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-19-17 11:43AM  3 Biotech Stocks to Be Thankful for This Year Motley Fool
Nov-17-17 08:10AM  Todays Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Myriad Genetics ACCESSWIRE -5.93%
Nov-13-17 07:50AM  Featured Company News - Infinity Shares Clinical and Translational Data from Monotherapy Dose-Escalation Component of Phase-1/1b Study for IPI-549 ACCESSWIRE
Nov-10-17 10:52AM  Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised Zacks
Nov-08-17 04:30PM  Stonegate Capital Partners Updates Coverage on Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) ACCESSWIRE
11:00AM  Why Spectrum Pharmaceuticals Stock Soared in October Motley Fool
07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th Business Wire
Nov-07-17 07:40AM  Recent Analysis Shows Philip Morris, Danaher, Skechers, Sally Beauty, Spectrum Pharma, and Textron Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-06-17 11:59AM  Top 4 Small-Cap Stocks for 2017 Investopedia
Nov-03-17 03:22PM  Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates Zacks
09:24AM  Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers TheStreet.com
Nov-02-17 05:33PM  Spectrum Pharma reports 3Q loss Associated Press
04:02PM  Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update Business Wire
12:10PM  Spectrum Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-31-17 04:39PM  Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store? Zacks
Oct-30-17 07:00AM  Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2 Business Wire
Oct-26-17 04:15PM  Harry Boxers three biotech-stock breakouts to watch MarketWatch
07:00AM  Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and Webcast Business Wire
Oct-21-17 10:32AM  3 Healthcare Stocks That Soared This Week: Are They Buys? Motley Fool
Oct-19-17 08:10AM  Today's Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Protalix BioTherapeutics ACCESSWIRE -5.39%
Oct-18-17 05:04PM  What Happened in the Stock Market Today Motley Fool +36.03%
04:58PM  Why Spectrum Pharmaceuticals Stock Jumped Higher Today Motley Fool
12:52PM  Four Biotech And Health Care Breakouts Forbes
12:40PM  Investors Race to Buy Spectrum Pharmaceuticals, Inc. (SPPI) Shares; Heres Why SmarterAnalyst
09:29AM  Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers TheStreet.com
08:50AM  Why Spectrum Pharmaceuticals Shares Are Surging 24/7 Wall St.
08:00AM  Today's Research Reports on Trending Tickers: Array BioPharma and Spectrum Pharmaceuticals ACCESSWIRE
Oct-17-17 10:15PM  Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan Business Wire
Oct-10-17 04:30PM  Stonegate Capital Partners Updates Coverage on Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) ACCESSWIRE
07:00AM  Spectrum Pharmaceuticals Announces Agreements to Exchange $69.5 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2018 for Common Stock and Cash Business Wire
Oct-09-17 12:02PM  ETFs with exposure to Spectrum Pharmaceuticals, Inc. : October 9, 2017 Capital Cube
Sep-30-17 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-29-17 10:38AM  ETFs with exposure to Spectrum Pharmaceuticals, Inc. : September 29, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: MannKind Corporation and Spectrum Pharmaceuticals ACCESSWIRE
07:00AM  Spectrum Pharmaceuticals Provides Update on At-The-Market Facility Business Wire
Sep-28-17 01:46PM  Here's Why Spectrum Pharmaceuticals, Inc. Is Surging Today Motley Fool +22.97%
07:00AM  Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017 Business Wire
Sep-05-17 07:00AM  Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September Business Wire
Sep-01-17 10:38AM  Evomelas Market Share Is Increasing in 2017 Market Realist
Aug-25-17 05:34PM  ETFs with exposure to Spectrum Pharmaceuticals, Inc. : August 25, 2017 Capital Cube
Aug-17-17 07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor Conference in Newport Beach on Thursday, August 24th Business Wire
Aug-16-17 05:44PM  Spectrum (SPPI) Initiates Phase II Study for Cancer Drug Zacks
10:28AM  Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Capital Cube
Aug-14-17 07:00AM  Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Business Wire
Aug-11-17 11:20PM  Edited Transcript of SPPI earnings conference call or presentation 3-Aug-17 8:30pm GMT Thomson Reuters StreetEvents +5.49%
Aug-08-17 11:14AM  Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised Zacks
Aug-07-17 08:20AM  Spectrum Pharmaceuticals (SPPI) Looks Good: Stock Jumps 22.2% Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Cara Therapeutics, Inc. and Spectrum Pharmaceuticals ACCESSWIRE
Aug-04-17 02:10PM  Why Spectrum Pharmaceuticals Stock Is Bolting Higher Today Motley Fool +22.24%
10:07AM  Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat Zacks
Aug-03-17 04:02PM  Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update Business Wire
12:30PM  Investor Network: Spectrum Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 07:00AM  Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS (eflapegrastim), a Novel Long-Acting GCSF Business Wire
Jul-27-17 07:00AM  Spectrum Pharmaceuticals Announces Second Quarter 2017 Financial Results Teleconference and Webcast Business Wire -6.48%
Jun-19-17 07:00AM  Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting Business Wire
Jun-12-17 02:57PM  Spectrum Pharmaceuticals, Inc. Value Analysis (NASDAQ:SPPI) : June 12, 2017 Capital Cube
Jun-09-17 08:35AM  Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SPPI-US : June 9, 2017 Capital Cube
Jun-02-17 07:00AM  Spectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 Business Wire
May-30-17 07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 Global Healthcare Conference on June 6th Business Wire
May-19-17 03:11PM  Edited Transcript of SPPI earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-16-17 07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017 Health Care Conference on May 17 Business Wire
May-08-17 05:15PM  ETFs with exposure to Spectrum Pharmaceuticals, Inc. : May 8, 2017 Capital Cube
May-05-17 10:29AM  Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 Capital Cube
08:55AM  Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SPPI-US : May 5, 2017 Capital Cube
May-04-17 01:36PM  Edited Transcript of SPPI earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-03-17 01:04PM  Why Spectrum Pharmaceuticals Stock Is Sinking Today Motley Fool -11.55%
10:09AM  Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma TheStreet.com
May-02-17 06:06PM  Spectrum Pharma reports 1Q loss Associated Press
04:02PM  Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update Business Wire
Apr-27-17 04:17PM  ETFs with exposure to Spectrum Pharmaceuticals, Inc. : April 27, 2017 Capital Cube
07:00AM  Spectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care Conference on May 4 Business Wire
Apr-25-17 07:00AM  Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference and Webcast Business Wire
Apr-21-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Celldex Therapeutics and Spectrum Pharmaceuticals Accesswire
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHROTRIYA RAJESH C MDDirectorJan 09Option Exercise7.605,199,58439,510,7846,988,631Jan 11 09:27 PM
SHROTRIYA RAJESH C MDChairman & CEONov 30Option Exercise3.15100,000315,000214,684Dec 04 07:42 PM
MAIDA ANTHONY E IIIDirectorJul 17Option Exercise6.9015,000103,50037,175Jul 18 06:02 PM
Krassner Stuart MitchellDirectorJul 17Option Exercise6.9015,000103,50067,444Jul 18 06:00 PM